A MAKHLOGH; M JAMSHIDI; V MOKHBERI
Volume 13, Issue 1 , March and April 2006, , Pages 14-18
Abstract
Background and purpose: Hyperlipidemia is one of the most important cardiovascular risk factors in hemodialysis patients. As adequate amount of carnation is essential for fatty acids metabolism and prevention of hyperlipidemia, This research was conducted to study the effect of carnitine on serum lipids ...
Read More
Background and purpose: Hyperlipidemia is one of the most important cardiovascular risk factors in hemodialysis patients. As adequate amount of carnation is essential for fatty acids metabolism and prevention of hyperlipidemia, This research was conducted to study the effect of carnitine on serum lipids in hemodialysis patients.
Methods and Materials: 20 patients with at least 3 months hemodialysis duration participated in this double-blind clinical trial. Randomly and equally, they were divided into two (case and control) groups. Cases received 1g carnitine and controls received placebo daily. Cholesterol and Triglyceride levels were measured prior to the study as well as 3 and 6 months after administration. SPSS package and ANOVA, t-test and chi-squre tests were used far analysis.
Results: There were not significant difference in mean of cholesterol and triglyceride levels in two groups as well as in repeated measurements. Also, no significaut changes were observed in each group 3 and 6 months after administration.
Conclusion: Carnitine did not have any effect on serum lipids in hemodialysis patients.